Abstract
Acute myeloid leukemia (AML) is a hematological malignancy with strong heterogeneity. Immune disorders are a feature of various malignancies, including AML. Interleukins (ILs) and other cytokines participate in a series of biological processes of immune disorders in the microenvironment, and serve as a bridge for communication between various cellular components in the immune system. The role of ILs in AML is complex and pleiotropic. It can not only play an anti-AML role by enhancing anti-leukemia immunity and directly inducing AML cell apoptosis, but also promote the growth, proliferation and drug resistance of AML. These properties of ILs can be used to explore their potential efficacy in disease monitoring, prognosis assessment, and development of new treatment strategies for AML. This review aims to clarify some of the complex roles of ILs in AML and their clinical applications.
Author contributions
Y. W. is responsible for the study design, summarizing relevant material and the writing of this article. X. T., Y. Z., X. Y. are responsible for collation of related references, and revision of manuscripts. B.L. designed, instructed and revised this article. All authors agree with the content of the article and are responsible for the authenticity of the content. All authors approved the typescript.
Disclosure statement
No potential conflict of interest was reported by the author(s).